Saturday 17 October 2026
Export CSBR’s income statement to Excel — free account
Champions Oncology, Inc.
CSBR Healthcare Biotechnology
Champions Oncology, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $59.4 million, up 4.36% from fiscal 2025. In the quarter to July 2026, revenue grew 8.84%, EPS was flat and free cash flow fell 198.7%, each against the same quarter a year earlier.
4.70
0.09
−1.88%
Follow CSBR
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 36.00 |
+8 more quarters Free account |
P/S ratio |
1.23 | 1.39 | 1.71 | 1.61 | |
P/FCF ratio |
0.00 | 0.00 | 25.79 | 16.73 | |
P/Operating CF |
(151.41) | (41.26) | (73.95) | (54.37) | |
P/B ratio |
16.70 | 20.27 | 22.62 | 22.30 | |
Price to Tangible BV |
18.06 | 22.08 | 24.49 | 24.21 | |
EV/Sales |
1.16 | 1.31 | 1.59 | 1.47 | |
EV/EBITDA |
225.82 | 327.69 | 0.00 | 23.49 | |
EV/Operating CF |
(12.62) | (17.37) | 20.93 | 13.81 | |
EV/FCF |
(11.49) | (15.50) | 23.96 | 15.23 | |
Quick Ratio |
0.96 | 0.91 | 0.93 | 0.91 | |
Current Ratio |
1.03 | 0.96 | 0.98 | 0.96 | |
Net Debt/EBITDA |
45.87 | 24.24 | (109.65) | (15.71) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.90 | 2.00 | 1.96 | 2.11 | |
Operating CF/Net income |
1.15 | 2.86 | 4.80 | (6.47) | |
Capex/Depreciation |
(0.18) | (0.74) | (0.04) | (0.68) | |
Research and Development Expense of Revenue |
15.39% | 15.29% | 13.71% | 17.40% | |
Selling, General and Administrative Expense of Revenue |
37.83% | 39.26% | 34.07% | 33.07% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
5.03% | 2.58% | 2.55% | 1.66% | |
Graham Net Nets |
(0.13) | (0.04) | (0.04) | (0.05) | |
Graham Number |
0.00 | 0.00 | 0.00 | 1.15 | |
Earnings Yield |
(1.49%) | (1.34%) | (2.24%) | 2.78% | |
Free Cash Flow Yield |
(8.21%) | (6.08%) | 3.88% | 5.98% | |
Revenue per Share |
1.10 | 1.00 | 1.19 | 1.09 | |
Operating CF per Share |
(0.04) | (0.14) | (0.10) | (0.13) | |
Capex per Share |
0.00 | (0.02) | 0.00 | (0.02) | |
Free Cash Flow per Share |
(0.04) | (0.16) | (0.10) | (0.14) | |
Cash per Share |
0.31 | 0.35 | 0.51 | 0.62 | |
Shareholders Equity per Share |
0.32 | 0.29 | 0.32 | 0.31 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.32 | 0.29 | 0.32 | 0.31 | |
Free Cash Flow |
(0.55) | (2.24) | (1.35) | (1.98) | |
Working Capital |
0.56 | (0.70) | (0.49) | (0.81) | |
Capital Expenditures |
(0.05) | (0.24) | (0.01) | (0.24) | |
Net Current Asset Value |
(9.54) | (3.70) | (3.88) | (4.60) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 39.96 | |
Capex to Sales |
0.00 | 0.02 | 0.00 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 43.88 | |
| Other line items | |||||
Average Receivables |
11.54 | 12.19 | 13.92 | 11.00 | |
Average Payables |
5.24 | 5.58 | 5.41 | 5.42 | |
Average Assets |
31.92 | 29.67 | 29.54 | 27.70 | |
Average Common Equity |
4.00 | 3.92 | 4.92 | 2.46 |
Columns are period end dates